BridgeBio Oncology Therapeutics Inc.
NASDAQ:BBOTBiotechnology
-$0.03 today
- Market cap
- $144.85M
- Beta
- 0.29
- P/E (TTM)
- -1.5
- EPS (TTM)
- -$4.95
Volume 0.58M
Average 0.37M
BBOT Total Liabilities
Everything the company owes to creditors and other parties.
BridgeBio Oncology Therapeutics Inc.NASDAQ: BBOT
Total Liabilities · Q1 FY2026 · quarter ended Mar 2026
Total liabilities falls 87.0% from a year ago
Total liabilities stood at $45.37M at the end of Q1 FY2026, down 87.0% from a year earlier and up 21.7% from the prior quarter. Over 3 fiscal years it compounded at +507.3% a year.
Context
- Total liabilities amounted to 10.9% of total assets at the end of Q1 FY2026, down 222.6 pp from a year earlier.
- Total liabilities increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether total liabilities keeps falling in the next quarterly balance sheet after a -87.0% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 37.29M USD
- Year-over-year change
- +553.3%
- 4-year CAGR
- +289.1%
| Period | Period end | Total Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 37.29M | +553.3% |
| FY2024 | 2024-12-31 | 5.71M | +1339.6% |
| FY2023 | 2023-12-31 | 396.46K | +138.2% |
| FY2022 | 2022-12-31 | 166.46K | +2.3% |
| FY2021 | 2021-12-31 | 162.64K | — |
Total Liabilities vs competitors
How BBOT compares with its peers on the latest reported figures
- Peers report in different currencies, so total liabilities is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of -87.0% is the lowest of 10, against a peer median of +1.5%.
- Total liabilities amounts to 10.9% of total assets for BBOT, versus a peer median of 30.9%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $642.08M USD | +1.5% | +42.8% | 210.4% | |
| Mar 2026 | $377.94M USD | +28.5% | +10.8% | 149.0% | |
| Mar 2026 | $316.94M USD | -18.3% | -2.1% | 96.1% | |
| Aug 2026 | $226.99M USD | +51.1% | +9.7% | 19.0% | |
| Jun 2026 | $221.73M USD | -14.4% | +26.4% | 30.6% | |
| Sep 2026 | $196.84M USD | +1.3% | -5.6% | 94.0% | |
SEPNSepterna, Inc. | Sep 2026 | $191.48M USD | -12.1% | +38.7% | 30.9% |
| Sep 2026 | $53.29M USD | +6.4% | -34.5% | 5.2% | |
| Mar 2026 | CHF 47.2M CHF | +13.6% | -33.4% | 19.4% | |
BBOTBridgeBio Oncology Therapeutics Inc. | Mar 2026 | $45.37M USD | -87.0% | +507.3% | 10.9% |
| Peer median (excluding BBOT) | — | +1.5% | +9.7% | 30.9% | |
Competitors are the stored peer set for BBOT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
BridgeBio Oncology Therapeutics Inc.
NASDAQ:BBOT
Intrinsic Alpha fair value
Locked
Current Price
$1.81
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.